I am sorry to hear of your mom's diagnoses. My sister, too, is diagnosed with cancer in Jan 08(cholangiocarcinoma-Bile Duct Cancer).
My recommendation is to get to Mayo Clinic if you can. They are so willing to evaluate and make recommendations for the best treatments available. Call them and see if they can help your mom:507-284-4137. You will reach; Christy, Terry or Mary.
Get all of your mother's records including all tests, results and the pathology reports. Mayo does not want them initially, they just want to get the info input into the computer for the medical staff to review. You will then get an appointment at Mayo for the evaluation team to review your mom's medical records (that you will bring with you) and after make recommendations. She can have any recommended treatments at Mayo or at your local Cancer Center or Clinic.
God Bless you in your quest to help your mom. Mainly, my recommendation is to love her, be with her as often as you can, call her, be informed through investigation of cancer reports, etc, and take care of yourself.
Cancer Compass just announced a new trial of using Triphendiol. See the article below.
Blessings,
My sister's voice
eaglessoar
April 21, 2008
BIRMINGHAM, Ala. -- A U.S. university study suggests the drug triphendiol causes tumor cell death in pancreatic and bile duct cancer, as well as slowing tumor growth.
The study by University of Alabama at Birmingham researchers led by Assistant Professor Ewan Tytler showed the drug also sensitizes tumors to chemotherapy treatments.
Tytler and his colleagues assessed the potential of triphendiol as a treatment for pancreatic adenocarcinoma using three representative cell lines. Triphendiol induced cell death in all three cell lines and pretreating the cell lines with triphendiol increased the effectiveness of chemotherapy.
Animal model studies showed triphendiol in combination with chemotherapy inhibited tumor growth even more effectively than each drug alone.
"In our laboratory studies, triphendiol is more potent at inducing cell death in pancreatic and bile duct cancer cells compared to the chemotherapy drug gemcitabine alone at up to 10-fold lower concentrations," Tytler said. "Of course, there is still much work to be done before this could become a treatment protocol for cancer patients, but our findings are promising and validate the continued development of triphendiol as a possible pancreatic cancer therapy."
Triphendiol is being developed by Marshall Edwards Inc., which funded Tytler's research.
The study that included Dr. Xiaohong Wang and Professor J. Anthony Thompson was presented last week in San Diego, during the annual meeting of the American Association for Cancer Research.